IMTX
Immatics N.V.
stockNASDAQ
immatics is a clinical-stage biopharmaceutical company active in the discovery and development of t-cell redirecting immunotherapies for the treatment of cancer. our transformative product candidates are - best in class - adoptive cell therapies and bispecific tcr molecules. these products are directed against tumor targets that have been identified and validated by immatics' proprietary and world-leading xpresident® technology. our mission is to bring the power of t-cell redirecting immunotherapies to cancer patients. quick facts - 150 team members - >100 targets covering 20 major solid and liquid tumors - about 80% of discovered targets are novel - 2 proprietary technology platforms - 8 proprietary development programs, thereof 2 in the clinic in 2017 - multiple partnered programs - raised more than $230m in cash in five financings read more about immatics on our homepage: https://immatics.com/ find us on twitter and xing: twitter: http://bit.ly/2dfbpre xing: http://bit.ly/2e1kkpv l
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 8.50 | 2026-09-28 | -10.88% | -12.627 |
| 1M | 9.56 | 2026-09-04 | -20.76% | 0.373 |
| 3M | 9.99 | 2026-07-06 | -24.17% | 0.920 |
| 6M | 10.31 | 2026-04-06 | -26.53% | 1.023 |
| 1Y | 9.40 | 2025-10-03 | -19.41% | 1.429 |
| 2Y | 10.86 | 2024-10-04 | -30.25% | — |
| 5Y | 12.95 | 2021-10-04 | -41.51% | 1.022 |
Immatics N.V. (NASDAQ:IMTX) stock price today is $7.58, and today's volume is 1,256,981. IMTX is down 10.249% today. The 30 day average volume is 751,623. IMTX market cap is $1.15B with 152.23M shares outstanding.